Here's the Bad News That Derailed Regeneron's Stock
This big-cap biotech has a problem or two on its hands.
Regeneron Pharmaceuticals
REGN
REGN
$311.80
-$8.29
-2.6%
BATS BZX Real Time Price as of May 23, 2019, 2:06 p.m.
View Interactive REGN Charts
The Company is a biopharmaceutical company that discovers, develops, and intends to commercialize pharmaceutical products for the treatment of serious medical conditions.
News & Analysis: Regeneron Pharmaceuticals
The Fool has written over 400 articles on Regeneron Pharmaceuticals.
All
Market Moves
Podcasts
Earnings
Regeneron Pharmaceuticals (REGN) Q1 2019 Earnings Call Transcript
REGN earnings call for the period ending March 31, 2019.
What's Behind Regeneron's Q1 Revenue and Earnings Misses
The big biotech disappointed investors in the first quarter with slower-than-expected revenue and earnings growth. Here's what you need to know.
Better Buy: Vertex Pharmaceuticals vs. Regeneron Pharmaceuticals
Which stock wins in a battle between these two successful biotechs?
3 Most Profitable Drugmakers in the S&P 500 -- Are They Buys?
These drugmakers' profit margins are sky-high. But does that necessarily mean they're great stocks to buy?
Regeneron Pharmaceuticals Inc (REGN) Q4 2018 Earnings Conference Call Transcript
REGN earnings call for the period ending December 31, 2018.
3 Top Biotech Stocks to Buy Right Now
Biotech may be a tough industry to invest in, but we've found three companies within that space that are worth looking into.
3 Healthcare Stocks Hitting 52-Week Highs: Are They Buys?
Can the sizzling momentum continue for these high-flying healthcare stocks?
Biotech Stocks Made Big Progress Toward Preventing Heart Attacks in 2018
Key trials suggest doctors may change how they treat patients with cardiovascular disease.
Is It Too Late to Get In on This Millionaire-Maker Stock?
Zoetis may not be a household name, but it's a pharma industry leader that has crushed the S&P 500 since making its 2013 public debut.
